EB 148: WHO’s COVID-19 Technology Access Pool (C-TAP) comes under scrutiny

On Tuesday, 19 January 2021, the World Health Organization’s (WHO) Executive Board discussed the COVID-19 response. In these discussions, Knowledge Ecology International (KEI), and Health Action International (HAI) expressed concerns over WHO’s leadership of the COVID-19 Technology Access Pool (C-TAP).… Continue Reading

KEI Comments to NIH on Exclusive and Co-Exclusive Licenses to Senti Bio

Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on January 12, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like… Continue Reading

KEI Comments on NIH Exclusive License to Morphiex for Cancer Treatment

(Update: The NIH provided a response to our comments on January 19, 2021) On January 12, 2021, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Use… Continue Reading

WHO informal consultation (3 December 2020) addressed concerns on price transparency and shortages

On Monday, 11 January 2021, the secretariat of the World Health Organization (WHO) published an 18 page report on the Global strategy and plan of action on public health, innovation and intellectual property (EB148/10). The Director-General’s report contains a detailed… Continue Reading

EB 148: WHO board paper on expanding access to effective treatments of cancer and rare and orphan diseases including cell and gene-based therapies

On 16 December 2020 the World Health Organization (WHO) published a paper that delighted in the name, Expanding access to effective treatments for cancer and rare and orphan diseases, including medicines, vaccines, medical devices, diagnostics, assistive products, cell- and gene-based… Continue Reading

KEI Comments on NIH Proposed Exclusive Patent License to St. Louis University for Treatment and Prevention of Neuropathic Pain With P2Y14 Antagonists

On December 3, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) regarding the “Prospective Grant of Exclusive Patent License: Treatment and Prevention of Neuropathic… Continue Reading

$1.8 Billion Sanofi Vaccine Contract Contains International Reference Pricing Clause, Preserves Standard IP and Data Rights

The contract awarding Sanofi Pasteur (“Sanofi”) 1.8 billion U.S. taxpayers’ dollars for the development and manufacture of a COVID-19 vaccine was posted in the Department of Health and Human Services (HHS) Electronic Reading Room on November 30, 2020. Overall, the… Continue Reading

Foundational mRNA patents are subject to the Bayh-Dole Act provisions

Katalin Karikó and Drew Weissman are often described as the pioneers of the mRNA discoveries that underpin the first COVID-19 vaccines. In 2005 both scientists published a paper reporting that a slightly tweaked version of mRNA that can be administered… Continue Reading